Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2007 2
2008 2
2009 1
2010 1
2011 3
2012 2
2013 2
2014 5
2015 3
2016 1
2017 1
2018 1
2019 3
2020 4
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. Among authors: nosslinger t. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP. Fürstenau M, et al. Among authors: nosslinger t. Blood. 2023 Aug 3;142(5):446-459. doi: 10.1182/blood.2023019634. Blood. 2023. PMID: 37172204 Clinical Trial.
Impact of age and comorbidity in myelodysplastic syndromes.
Stauder R, Nösslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O, Valent P. Stauder R, et al. Among authors: nosslinger t. J Natl Compr Canc Netw. 2008 Oct;6(9):927-34. doi: 10.6004/jnccn.2008.0070. J Natl Compr Canc Netw. 2008. PMID: 18926101 Review.
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial.
Keil F, Müller AMS, Berghold A, Riedl R, Buxhofer-Ausch V, Schuster J, Vorburger C, Böhm A, Panny M, Nösslinger T, Greil R, Samaras P, Bencker C, Rütti M, Pabst T. Keil F, et al. Among authors: nosslinger t. EClinicalMedicine. 2023 Nov 19;66:102318. doi: 10.1016/j.eclinm.2023.102318. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38024477 Free PMC article.
Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Nösslinger T, Pfeilstöcker M, Machherndl-Spandl S, Stauder R, Zebisch A, Sill H, Öhler L, Kusec R, Hoermann G, Valent P. Geissler K, et al. Among authors: nosslinger t. Eur J Haematol. 2022 Jul;109(1):50-57. doi: 10.1111/ejh.13768. Epub 2022 Mar 23. Eur J Haematol. 2022. PMID: 35299281 Free PMC article.
[Individualized management and therapy of myelodysplastic syndromes].
Stauder R, Wimazal F, Nösslinger T, Krieger O, Sperr WR, Sill H, Pfeilstöcker M, Valent P. Stauder R, et al. Among authors: nosslinger t. Wien Klin Wochenschr. 2008;120(17-18):523-37. doi: 10.1007/s00508-008-1058-6. Wien Klin Wochenschr. 2008. PMID: 18988005 Review. German.
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Machherndl-Spandl S, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Geissler C, Hoermann G, Nösslinger T, Pfeilstöcker M, Bettelheim P, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Kusec R, Ulsperger E, Schneeweiss B, Öhler L, Germing U, Valent P, Tüchler H, Geissler K. Machherndl-Spandl S, et al. Among authors: nosslinger t. Eur J Haematol. 2021 Aug;107(2):265-274. doi: 10.1111/ejh.13647. Epub 2021 Jun 1. Eur J Haematol. 2021. PMID: 33998054 Free PMC article.
Thromboembolic events during treatment with thalidomide.
Urbauer E, Kaufmann H, Nösslinger T, Raderer M, Drach J. Urbauer E, et al. Among authors: nosslinger t. Blood. 2002 Jun 1;99(11):4247-8. doi: 10.1182/blood-2001-12-0245. Blood. 2002. PMID: 12043695 Free article. Clinical Trial. No abstract available.
35 results